Esprolol, also known as (S)-ACC-9369, is a beta blocker which was under development for the treatment of angina pectoris, anxiety disorders, and migraine.[1][3][2] It is taken sublingually and has a rapid onset of action, short time to peak, and short duration.[1][2] The drug is a prodrug of amoxolol, which is formed from esprolol via esterase enzymes.[2] It is a selective β1-adrenergic receptor antagonist.[2][4] Esprolol was under development by Selectus Pharmaceuticals.[1][3] It reached phase 2 clinical trials for all indications prior to the discontinuation of its development in 2001.[1][3]

See also

References

  1. 1 2 3 4 5 6 "Esprolol". AdisInsight. 25 June 2001. Retrieved 5 June 2026.
  2. 1 2 3 4 5 6 7 8 9 Matier WL, Patil G (2000). "Esprolol hydrochloride: a new beta adrenergic antagonist with a rapid onset of effect". Heart Dis. 2 (2): 146–150. PMID 11728252.
  3. 1 2 3 "Delving into the Latest Updates on Esprolol Hydrochloride with Synapse". Synapse. 30 May 2026. Retrieved 5 June 2026.
  4. ↑ Frishman WH, Alwarshetty M (2002). "Beta-adrenergic blockers in systemic hypertension: pharmacokinetic considerations related to the current guidelines". Clin Pharmacokinet. 41 (7): 505–516. doi:10.2165/00003088-200241070-00004. PMID 12083978. A sublingual β1-selective blocker, esprolol, is now being evaluated in clinical trials.[30]
source: https://en.wikipedia.org/wiki/Esprolol